Katarina Ageborg - AstraZeneca PLC Chief Compliance Officer

All Insiders . USA . 
Stock . AstraZeneca PLC . Stakeholders . Insider . Katarina Ageborg
AZNCF Stock  USD 131.74  0.68  0.51%   

Executive

Ms. Katarina Ageborg is Executive Vice President Sustainability, Chief Compliance Officer of AstraZeneca PLC since 2011.
Tenure 13 years
Phone44 20 3749 5000
Webhttps://www.astrazeneca.com
Katarina was appointed Executive VicePresident, Sustainability in 2017 and was a member of SET since 2011. She has overall responsibility for the delivery, design and implementation of the Company’s sustainability programme, covering three priority areas: access to healthcare; environmental protection; and ethics and transparency. She leads the Global Sustainability function, including teams focusing on Compliance, and Safety, Health and Environment. Katarina was also appointed President of AstraZeneca AB in 2018, and her role is focused on strengthening corporate reputation and relations by actively representing the company in the Swedish business and academic community. Prior to her current roles, Katarina led the Global Intellectual Property function from 2008 to 2011, during which time she streamlined the organisation and launched a new patent filing strategy before taking the role as Chief Compliance Officer

AstraZeneca PLC Management Efficiency

The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.
AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 0.87, which is about average as compared to similar companies. AstraZeneca PLC has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Sloan SimpsonNovartis AG ADR
N/A
Madeleine RoachSanofi ADR
40
Giovanni MDBristol Myers Squibb
59
Susan MDAstraZeneca PLC ADR
58
Charles SawyersNovartis AG ADR
62
Aharon GalNovartis AG ADR
N/A
FranoisXavier RogerSanofi ADR
62
Jeffrey JDAstraZeneca PLC ADR
N/A
William WintersNovartis AG ADR
60
Samit MDBristol Myers Squibb
55
Deborah TelmanGilead Sciences
59
Ruth MarchAstraZeneca PLC ADR
N/A
Klaus MoosmayerNovartis AG ADR
56
Rudolf ErtlGilead Sciences
78
Steven BaertNovartis AG ADR
45
Steffen LangNovartis AG ADR
57
Vasant NarasimhanNovartis AG ADR
48
Andrew BarnettAstraZeneca PLC ADR
N/A
Kimberly JablonskiBristol Myers Squibb
N/A
Ahn PooleBristol Myers Squibb
49
Adrian KempAstraZeneca PLC ADR
N/A
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 83100 people. AstraZeneca PLC [AZNCF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.0863
Return On Asset0.0531

AstraZeneca PLC Leadership Team

Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, CFO and Executive Director
Chris Sheldon, Head Relations
Pam Cheng, Executive Vice-President of Operations and Information Technology
MBA DVM, CEO Director
Gonzalo Vina, Head Relations
Aradhana MD, CFO Director
Menelas Pangalos, Executive Vice President - Innovative Medicines
Katarina Ageborg, Chief Compliance Officer
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President Europe

AstraZeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0863
Return On Asset0.0531
Profit Margin0.07 %
Operating Margin0.19 %
Current Valuation241.1 B
Shares Outstanding1.55 B
Shares Owned By Insiders0.22 %
Shares Owned By Institutions48.84 %
Price To Earning44.18 X
Price To Book6.16 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in AstraZeneca Pink Sheet

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY